Jason Rickard Net Worth

The estimated Net Worth of Jason Rickard is at least 4.8 百万$ dollars as of 27 February 2023. Mr Rickard owns over 34,175 units of Ironwood Pharmaceuticals Inc stock worth over 1,447,019$ and over the last 5 years he sold IRWD stock worth over 2,416,655$. In addition, he makes 940,064$ as COO & Sr. VP of Operations at Ironwood Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Rickard IRWD stock SEC Form 4 insiders trading

Mr has made over 14 trades of the Ironwood Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 34,175 units of IRWD stock worth 388,228$ on 27 February 2023.

The largest trade he's ever made was selling 47,477 units of Ironwood Pharmaceuticals Inc stock on 8 August 2022 worth over 554,531$. On average, Mr trades about 10,639 units every 51 days since 2020. As of 27 February 2023 he still owns at least 332,648 units of Ironwood Pharmaceuticals Inc stock.

You can see the complete history of Mr Rickard stock trades at the bottom of the page.

Mr. Jason Rickard biography

Jason Rickard is the COO & Sr. VP of Operations at Ironwood Pharmaceuticals Inc.

What is the salary of Mr Rickard?

As the COO & Sr. VP of Operations of Ironwood Pharmaceuticals Inc, the total compensation of Mr Rickard at Ironwood Pharmaceuticals Inc is 940,064$. There are 5 executives at Ironwood Pharmaceuticals Inc getting paid more, with Mark Mallon having the highest compensation of 10,068,800$.

How old is Mr Rickard?

Mr Rickard is 50, he's been the COO & Sr. VP of Operations of Ironwood Pharmaceuticals Inc since . There are 13 older and 5 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.

What's Mr Rickard's mailing address?

Jason's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.

Insiders trading at Ironwood Pharmaceuticals Inc

Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over 83,928,361$ worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth 24,100,589$ . The most active insiders traders include Llc Fmr、Bryan E Roberts、Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of 239,611$. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth 42,316$.

What does Ironwood Pharmaceuticals Inc do?

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Complete history of Mr Rickard stock trades at Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc executives and stock owners

Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Mallon,
  Chief Executive Officer, Director
• Thomas McCourt,
  President
• Mark Currie,
  Director
• Gina Consylman,
  Chief Financial Officer, Senior Vice President
• Thomas A. McCourt,
  CEO & Director
• Jason Rickard,
  COO & Sr. VP of Operations
• Dr. Michael Shetzline M.D., Ph.D.,
  Chief Medical Officer, Sr. VP and Head of R&D
• Catherine Moukheibir,
  Independent Director
• Jon Duane,
  Independent Director
• Marla Kessler,
  Independent Director
• Julie McHugh,
  Independent Chairman of the Board
• Andrew Dreyfus,
  Independent Director
• Edward Owens,
  Independent Director
• Lawrence Olanoff,
  Independent Director
• Julie H. McHugh,
  Exec. Chairman
• Alexander Denner,
  Director
• Meredith Kaya,
  Vice President - Investor Relations and Corporate Communications
• Michael Shetzline,
  Chief Medical Officer, Senior Vice President and Head of Drug Development
• Conor Kilroy,
  Senior Vice President, General Counsel
• Jason Rickard,
  Chief Operating Officer, Senior Vice President
• John Minardo,
  Sr. VP & Chief Legal Officer
• Marcel Moulaison,
  VP of Technical Operations
• Ronald Silver,
  Corp. Controller & Principal Accounting Officer
• Sravan Kumar Emany,
  Sr. VP & CFO
• G. Todd Milne,
  Co-Founder and VP of sGC R&D
• Brian M. Cali,
  Co-Founder and Sr. VP of R&D Strategy & External Innovation
• Terrance Mcguire,
  Director
• Douglas E Williams,
  Director
• Amy W Schulman,
  Director
• Marsha Fanucci,
  Director
• Christopher T Phd Walsh,
  Director
• Peter M Hecht,
  Chief Executive Officer
• Thomas Graney,
  Chief Financial Officer
• William Huyett,
  Chief Operating Officer
• Halley E Gilbert,
  Chief Admin Officer & SVP
• Bryan E Roberts,
  Director
• Associatesvenrock Associate...,
  
• Management Llc Vr,
  10% owner
• Llc Fmr,
  10% owner
• Llcfil Ltd Fmr,
  
• Co Investment Holdings, Llc...,
  
• Capital Investments L.P.Rid...,
  
• Joseph C Jr Cook,
  Director
• George H Conrades,
  Director
• David Evans Shaw,
  Director
• David A Ebersman,
  Director
• Michael J Higgins,
  Chief Operating Officer
• Kelly Mac Donald,
  Chief Accounting Officer
• Jay Shepard,
  
• Sravan Kumar Emany,
  SVP, Chief Financial Officer
• Alexander J Sarissa Capital...,
  
• Andrew Davis,
  SVP, Chief Business Officer
• Ronald Silver,
  Principal Accounting Officer
• Minardo John,
  Chief Legal Officer